Xtant Medical Holdings reported a Q3 2026 net loss of $3.6 million, a sharp decline from the $1.3 million profit recorded in the same period last year. Following two consecutive quarters of missed guidance, the company has withdrawn its full-year 2026 outlook and initiated a board-led strategic review to evaluate potential partnerships, restructurings, or asset dispositions to maximize shareholder value.
Xtant missed its guidance for the second consecutive quarter, withdrew full-year 2026 guidance without a replacement, and swung to a Q3 2026 net loss of $3.6 million ($0.03/share) from $1.3 million net income a year earlier, with gross margin down to 56.3% from 66.1%. Cash fell to $7.8 million with only $2.1 million of revolver availability. The biologics growth (revenue $19.3 million, +13% y/y) and the board-led strategic review are offsets that could support the stock, but no outcome or timetable is assured.
- ▼ Board-led strategic review evaluating partnerships, restructurings, financings, acquisitions or dispositions
- ▼ Biologics revenue of $19.3 million, up 13% year-over-year and 11% quarter-over-quarter, including $2.2 million from HEMOBLAST Bellows
- ▲ Second consecutive quarter missing guidance and full-year 2026 guidance withdrawn with no replacement
- ▲ Net loss of $3.6 million versus prior-year net income of $1.3 million; adjusted EBITDA loss of $1.5 million